Courtney Marabella | Authors


Olaparib Improves Disease–Free Survival in Early HER2-Negative Breast Cancer

July 20, 2021

Patients who recived olaparib after a median follow-up of 2.5 years revealed a 42% reduction in invasive disease–free survival, including local and metastatic recurrence of breast cancer, other new cancers, and death due to any cause.